March 2024, Vol 5, No 1

Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.

Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.

FIRST-308 is an open-label, phase 2, randomized, global, multicenter study that will evaluate the efficacy and safety of oral tinengotinib versus physician’s choice in patients with fibroblast growth factor receptor (FGFR)-altered, chemotherapy- and FGFR inhibitor-refractory/relapsed cholangiocarcinoma—this article will review the study’s eligibility criteria, primary endpoints, and more.